Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications

被引:212
作者
Clerico, A
Recchia, FA
Passino, C
Emdin, M
机构
[1] CNR, Inst Clin Physiol, Lab Cardiovasc Endocrinol & Cell Biol, I-56126 Pisa, Italy
[2] Scuola Super Sant Anna, Pisa, Italy
[3] New York Med Coll, Valhalla, NY USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2006年 / 290卷 / 01期
关键词
atrial natriuretic peptide; brain natriuretic peptide; cardiac natriuretic hormones; cardiac function; heart failure; cardiovascular diseases;
D O I
10.1152/ajpheart.00684.2005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The discovery of cardiac natriuretic hormones required a profound revision of the concept of heart function. The heart should no longer be considered only as a pump but rather as a multifunctional and interactive organ that is part of a complex network and active component of the integrated systems of the body. In this review, we first consider the cross- talk between endocrine and contractile function of the heart. Then, based on the existing literature, we propose the hypothesis that cardiac endocrine function is an essential component of the integrated systems of the body and thus plays a pivotal role in fluid, electrolyte, and hemodynamic homeostasis. We highlight those studies indicating how alterations in cardiac endocrine function can better explain the pathophysiology of cardiovascular diseases and, in particular of heart failure, in which several target organs develop a resistance to the biological action of cardiac natriuretic peptides. Finally, we emphasize the concept that a complete knowledge of the cardiac endocrine function and of its relation with other neurohormonal regulatory systems of the body is crucial to correctly interpret changes in circulating natriuretic hormones, especially the brain natriuretic peptide.
引用
收藏
页码:H17 / H29
页数:13
相关论文
共 193 条
[1]   EFFECT OF CONVERTING-ENZYME INHIBITION ON RENAL RESPONSE TO ANF IN RATS WITH EXPERIMENTAL HEART-FAILURE [J].
ABASSI, Z ;
HARAMATI, A ;
HOFFMAN, A ;
BURNETT, JC ;
WINAVER, J .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 259 (01) :R84-R89
[2]   Vascular actions of natriuretic peptides - Cyclic GMP-dependent and -independent mechanisms [J].
Ahluwalia, A ;
MacAllister, RJ ;
Hobbs, AJ .
BASIC RESEARCH IN CARDIOLOGY, 2004, 99 (02) :83-89
[3]   Natriuretic peptide receptor-C signaling and regulation [J].
Anand-Srivastava, MB .
PEPTIDES, 2005, 26 (06) :1044-1059
[4]   Natriuretic peptide gene expression after β-adrenergic stimulation in adult mouse cardiac myocytes [J].
Ander, AN ;
Duggirala, SK ;
Drumm, JD ;
Roth, DM .
DNA AND CELL BIOLOGY, 2004, 23 (09) :586-591
[5]   Plasma concentrations of atrial, brain, and C-type natriuretic peptides and endothelin-1 in patients with chronic respiratory diseases [J].
Ando, T ;
Ogawa, K ;
Yamaki, K ;
Hara, M ;
Takagi, K .
CHEST, 1996, 110 (02) :462-468
[6]   Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones [J].
Andreassi, MG ;
Del Ry, S ;
Palmieri, C ;
Clerico, A ;
Biagini, A ;
Giannessi, D .
EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (04) :407-414
[7]   Natriuretic peptides and myocardial ischaemia [J].
Baxter, GF .
BASIC RESEARCH IN CARDIOLOGY, 2004, 99 (02) :90-93
[8]   The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma [J].
Belenky, A ;
Smith, A ;
Zhang, B ;
Lin, S ;
Despres, N ;
Wu, AHB ;
Bluestein, BI .
CLINICA CHIMICA ACTA, 2004, 340 (1-2) :163-172
[9]  
Benedict Claude R., 1994, Cardiology Clinics, V12, P9
[10]   Serum N-terminal pro-atrial natriuretic factor 1-98 before and during thyroxine replacement therapy in severe hypothyroidism [J].
Bernstein, R ;
Midtbo, K ;
Urdal, P ;
Morkrid, L ;
Smith, G ;
Muller, C ;
Bjoro, T ;
Haug, E .
THYROID, 1997, 7 (03) :415-419